Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Pei-Ran Ho
Effect of Natalizumab on Disease Progression in Secondary Progressive Multiple Sclerosis (ASCEND): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial With an Open-Label Extension
The Lancet Neurology
Neurology
Statistical Analysis of PML Incidences of Natalizumab-Treated Patients From 2009 to 2016: Outcomes After Introduction of the Stratify JCV® DxSelect™ Antibody Assay
Journal of NeuroVirology
Virology
Neurology
Cellular
Molecular Neuroscience
Related publications
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
New England Journal of Medicine
Medicine
Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial
The Lancet
Medicine
OP0208 a Proof-Of-Concept Double-Blind Randomised Placebo-Controlled Trial of Probiotics in Systemic Sclerosis Associated Gastrointestinal Disease
Etanercept in Alzheimer Disease: A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Trial
Neurology
Neurology
Limited Effect of Sulphasalazine Treatment in Reactive Arthritis. A Randomised Double Blind Placebo Controlled Trial
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Randomised, Double-Blind, Placebo-Controlled Trial of EPs 7630 in Adults With COPD
Respiratory Medicine
Pulmonary
Respiratory Medicine
Tocilizumab in Patients With Adult-Onset Still’s Disease Refractory to Glucocorticoid Treatment: A Randomised, Double-Blind, Placebo-Controlled Phase III Trial
Annals of the Rheumatic Diseases
Immunology
Molecular Biology
Biochemistry
Rheumatology
Allergy
Genetics
Bumetanide in Hypokalaemic Periodic Paralysis: A Randomised, Double-Blind, Placebo Controlled Phase II Clinical Trial With a Crossover Design
Neuromuscular Disorders
Child Health
Neurology
Pediatrics
Perinatology
Genetics
Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial
SKIN The Journal of Cutaneous Medicine
